Board member Mansoor Mirza exits Karyopharm (NASDAQ: KPTI) role

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. reported that board member Dr. Mansoor Raza Mirza has resigned from its Board of Directors, effective September 8, 2025, citing competing professional demands. The company states his resignation is not due to any disagreement regarding its operations, policies or practices.

Dr. Mirza is also resigning as Chief Oncologist at Copenhagen University National Medical Center effective October 1, 2025 to focus on a new executive role in industry. In connection with his departure from the board, the consulting agreement between Karyopharm and Mirza Consulting, an entity wholly owned by Dr. Mirza, was terminated effective September 8, 2025.

false000150380200015038022025-09-052025-09-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 5, 2025

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36167				26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)				(IRS Employer Identification No.)
85 Wells Avenue, 2nd Floor Newton, Massachusetts				02459
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza’s resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KARYOPHARM THERAPEUTICS INC.
Date: September 11, 2025				By:		/s/ Michael Mano
						Michael Mano
						Senior Vice President, General Counsel and Secretary

FAQ

What board change did Karyopharm Therapeutics (KPTI) disclose?

Karyopharm Therapeutics disclosed that Dr. Mansoor Raza Mirza, a member of its Board of Directors, notified the company of his resignation from the Board, effective September 8, 2025.

Why is Dr. Mansoor Raza Mirza resigning from Karyopharm's board?

The company states that Dr. Mirza’s resignation is due to competing professional demands and is not the result of any disagreement with Karyopharm on its operations, policies or practices.

When do Dr. Mirza’s resignations take effect?

His resignation from Karyopharm’s Board is effective September 8, 2025. His resignation as Chief Oncologist at Copenhagen University National Medical Center is effective October 1, 2025.

Did Karyopharm report any disagreement with Dr. Mirza?

No. Karyopharm states that Dr. Mirza’s resignation is not due to any disagreement with the company on matters related to its operations, policies or practices.

What happened to the consulting agreement with Mirza Consulting?

In connection with Dr. Mirza’s resignation from the Board, the consulting agreement between Karyopharm and Mirza Consulting, which is wholly owned by him, was terminated effective September 8, 2025.

Who signed the Karyopharm (KPTI) 8-K related to this board change?

The report was signed on behalf of Karyopharm Therapeutics Inc. by Michael Mano, Senior Vice President, General Counsel and Secretary.